STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its upcoming participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, May 20 at 12:00 p.m. ET. Investors can access both the live webcast and a 90-day archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-5.84% News Effect

On the day this news was published, AVDL declined 5.84%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162


FAQ

When is Avadel Pharmaceuticals (AVDL) presenting at the H.C. Wainwright BioConnect Conference?

Avadel Pharmaceuticals will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20 at 12:00 p.m. ET.

How can investors access Avadel Pharmaceuticals' (AVDL) presentation at the H.C. Wainwright Conference?

Investors can access the live webcast and archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.

How long will Avadel Pharmaceuticals' (AVDL) H.C. Wainwright Conference presentation be available for replay?

The archived recording of the presentation will be available on Avadel's Investor Relations website for 90 days following the conference.

What type of presentation will Avadel Pharmaceuticals (AVDL) give at the H.C. Wainwright Conference?

Avadel Pharmaceuticals' management will participate in a fireside chat format presentation at the conference.
Avadel Pharmaceu

NASDAQ:AVDL

AVDL Rankings

AVDL Latest News

AVDL Latest SEC Filings

AVDL Stock Data

2.09B
97.12M
4.89%
86.45%
10.8%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2